Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 long-term study of K-911 (bimatoprost grenod) in glaucoma or ocular hypertension
jRCT2051250049Phase 3Recruiting
- Sponsor
- Kowa Company, Ltd.
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of K-911 in open-angle glaucoma (OAG), pseudoexfoliation glaucoma (PXG), pigmentary glaucoma (PG) and 1 more, sponsored by Kowa Company, Ltd. Primary endpoints: Change from baseline in intraocular pressure at 2 weeks (16:00) and Incidence of adverse events and side effects. Started Jul 2025; status: recruiting.
02
Drugs
K-911
03
Conditions
open-angle glaucoma (OAG)pseudoexfoliation glaucoma (PXG)pigmentary glaucoma (PG)ocular hypertension
Beyond the preview
Go deeper on jRCT2051250049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051250049.